90 Percent of Surveyed U.S. Neurologists Report Willingness to Prescribe Biogen Idec’s BG-12

BURLINGTON, Mass., May 14, 2012 (BUSINESS WIRE) — Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that 90 percent of U.S. neurologists surveyed report a willingness to prescribe Biogen Idec’s BG-12 for the treatment of multiple sclerosis following the release of detailed results from the CONFIRM Phase III clinical trial, which were showcased at the 64th annual meeting of the American Academy of Neurology (AAN) in April 2012 (data for the twice daily dose were presented to respondents). Seventy percent of surveyed neurologists recall a willingness to prescribe BG-12 before full CONFIRM data were available, suggesting that the latest results were effective in improving overall physician receptivity to the drug. According to Snapshot: AAN 2012, data on BG-12 were among the multiple sclerosis-related topics most top-of-mind for surveyed neurologists following AAN 2012.

“In the CONFIRM trial, BG-12 demonstrated favorable efficacy against placebo and against Teva’s Copaxone, a reference arm in the study and surveyed neurologists’ most prescribed disease-modifying therapy for the treatment of relapsing-remitting multiple sclerosis,” said Decision Resources Analyst Jonathan Searles. “The efficacy data coupled with strong safety and tolerability results that are consistent with findings from the first Phase III study of BG-12–the DEFINE study–appear to have increased surveyed neurologists’ willingness to prescribe BG-12 overall.”

Snapshot: AAN 2012 is a new report from Decision Resources that through a survey of 50 U.S. neurologists offers rapid assessment of neurologists’ evolving opinion of select new developments in multiple sclerosis, including drug development updates from the recently concluded AAN conference. In addition to assessing neurologists’ opinions on BG-12, the Snapshot examines physician opinion on other multiple sclerosis news, including:

Read More